HUP0400005A3 - Use of osteopontin for the treatment and/or prevention of neurologic diseases - Google Patents

Use of osteopontin for the treatment and/or prevention of neurologic diseases

Info

Publication number: HUP0400005A3
Authority: HU; Hungary
Prior art keywords: osteopontin; prevention; treatment; neurologic diseases; neurologic
Prior art date: 2001-05-17

Application number

HU0400005A

Other languages

English (en)

Original Assignee

Serono Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-17

Filing date

2002-05-08

Publication date

2012-09-28

2002-05-08 Application filed by Serono Lab filed Critical Serono Lab

2004-04-28 Publication of HUP0400005A2 publication Critical patent/HUP0400005A2/hu

2012-09-28 Publication of HUP0400005A3 publication Critical patent/HUP0400005A3/hu

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Epidemiology (AREA)
Immunology (AREA)
Obesity (AREA)
Psychology (AREA)
Toxicology (AREA)
Psychiatry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Hematology (AREA)
Rheumatology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)

HU0400005A 2001-05-17 2002-05-08 Use of osteopontin for the treatment and/or prevention of neurologic diseases HUP0400005A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP01111296		2001-05-17
PCT/EP2002/005081 WO2002092122A2 (en)	2001-05-17	2002-05-08	Use of osteopontin for the treatment and/or prevention of neurologic diseases

Publications (2)

Publication Number	Publication Date
HUP0400005A2 HUP0400005A2 (hu)	2004-04-28
HUP0400005A3 true HUP0400005A3 (en)	2012-09-28

Family

ID=8177366

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU0400005A HUP0400005A3 (en)	2001-05-17	2002-05-08	Use of osteopontin for the treatment and/or prevention of neurologic diseases

Country Status (26)

Country	Link
US (4)	US7217687B2 (hu)
EP (1)	EP1389130B1 (hu)
JP (2)	JP4417632B2 (hu)
KR (1)	KR100947424B1 (hu)
CN (2)	CN1939538A (hu)
AT (1)	ATE555803T1 (hu)
AU (1)	AU2002312886B2 (hu)
BG (1)	BG108337A (hu)
BR (1)	BR0209812A (hu)
CA (1)	CA2443964A1 (hu)
CZ (1)	CZ20033109A3 (hu)
EA (1)	EA006655B1 (hu)
EE (1)	EE200300559A (hu)
ES (1)	ES2387082T3 (hu)
HR (1)	HRP20030840A2 (hu)
HU (1)	HUP0400005A3 (hu)
IL (2)	IL158867A0 (hu)
MX (1)	MXPA03010327A (hu)
NO (1)	NO20035025D0 (hu)
NZ (1)	NZ528852A (hu)
PL (1)	PL211763B1 (hu)
SK (1)	SK14232003A3 (hu)
UA (1)	UA85368C2 (hu)
WO (1)	WO2002092122A2 (hu)
YU (1)	YU89503A (hu)
ZA (1)	ZA200307956B (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2002341488A1 (en)	2001-05-09	2002-11-18	Biovision Ag	Method for detecting progredient chronic dementia, and associated peptides and detection reagents
JP2005519033A (ja) *	2001-11-21	2005-06-30	ザボードオブトラスティーズオブレランドスタンフォードジュニアユニバーシティ	オステオポンチン関連組成物および方法
JP2005535313A (ja) *	2002-06-25	2005-11-24	アベンティス・ファーマスーティカルズ・インコーポレイテツド	オステオポンチン、オリゴデンドロサイトおよび髄鞘形成
WO2004013311A2 (en) *	2002-08-06	2004-02-12	Diadexus, Inc.	Compositions and methods relating to ovarian specific genes and proteins
MXPA05010414A (es) *	2003-03-28	2005-12-14	Applied Research Systems	Uso de clusterina para el tratamiento y/o prevencion de enfermedades neurologicas perifericas.
WO2005025333A1 (en) *	2003-09-18	2005-03-24	Arla Foods Amba	Infant formula
EP2301569B1 (en)	2003-11-12	2018-05-02	Yeda Research and Development Co. Ltd.	Vaccine and method for treatment of neurodegenerative diseases
US7790687B2 (en) *	2005-02-18	2010-09-07	Proximagen Ltd.	Treatment for neurodegeneration
US20060264371A1 (en) *	2005-02-18	2006-11-23	Proximagen Ltd.	Treatment
CA2624916A1 (en)	2005-10-13	2007-04-26	Anthrogenesis Corporation	Production of oligodendrocytes from placenta-derived stem cells
EP1870107A1 (en) *	2006-06-23	2007-12-26	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of inducer of promyelocytic leukemia protein (PML) for treating polyglutamine expansion neurodegenerative diseases
WO2008086449A2 (en) *	2007-01-09	2008-07-17	Oregon Health & Science University	Synthetic osteopontin peptides and methods of use
US20100069254A1 (en) *	2008-09-16	2010-03-18	Laree Hiser	Cell Culture Model for Demyelination/Remyelination
KR101449100B1 (ko)	2011-04-21	2014-10-13	가톨릭대학교 산학협력단	신경세포 데브리스 제거용 오스테오폰틴
GB2493540A (en) *	2011-08-10	2013-02-13	Follicum Ab	Agents for stimulating hair growth in mammals
KR101728808B1 (ko) *	2012-09-28	2017-04-20	한국생명공학연구원	아세카이니드 또는 이의 유도체를 포함하는 근력약화 관련 질환의 예방 또는 치료용 약학적 조성물
EP3985394A1 (en) *	2014-08-27	2022-04-20	Dana-Farber Cancer Institute, Inc.	Intracellular osteopontin regulates the lineage commitment of lymphoid subsets
WO2017201539A1 (en) *	2016-05-20	2017-11-23	Cedars-Sinai Medical Center	Methods of treating or preventing alzheimer's disease and associated conditions
CN109996810B (zh) *	2016-11-27	2023-08-22	特里同阿盖亚创新公司	从微藻中纯化重组骨桥蛋白的方法
BR112019021886A2 (pt)	2017-05-04	2020-06-02	Follicum Ab	Peptídeos para o tratamento de diabetes
CN111315394A (zh) *	2017-08-15	2020-06-19	儿童医疗中心有限公司	作为用于神经元病变的治疗剂的骨桥蛋白
EP3801482A4 (en) *	2018-05-25	2022-06-29	The Children's Medical Center Corporation	Methods for treating spinal cord injury
TR201903865A2 (tr) *	2019-03-14	2020-09-21	Bogazici Ueniversitesi	Amyotrofi̇k lateral skleroz tedavi̇si̇ i̇çi̇n i̇nterferon kullanimi
WO2021024265A1 (en) *	2019-08-08	2021-02-11	Ramot At Tel-Aviv University Ltd.	Methods of treating non-infectious inflammatory disorders
CN111388654A (zh) *	2020-05-22	2020-07-10	南通大学	治疗脊髓损伤的药物、药物试剂盒及方法
EP4159223A4 (en) *	2020-06-02	2024-07-17	The Catholic University Of Korea Industry-Academic Cooperation Foundation	Composition comprising osteopontin inhibitor as active ingredient for prevention, alleviation, or treatment of neurodegenerative disease
CN117720620B (zh) *	2023-12-13	2024-07-23	无锡市儿童医院	小分子多肽和其药物组合物、其制药用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2245833T5 (es) *	1998-12-22	2013-07-19	Genentech, Inc.	Antagonistas del factor de crecimiento celular del endotelio vascular y usos de los mismos
AU773350B2 (en) *	1999-04-15	2004-05-20	Children's Medical Center Corporation	Methods and compositions for modulating an immune response
AU3667100A (en)	1999-04-23	2000-11-10	Sulzer Orthopedics Ltd	Composition for enhancing functional recovery of a mammal from central and/or peripheral nervous system injury of traumatic or pathological origin
EP1221975B1 (en) *	1999-10-04	2006-12-06	Nektar Therapeutics Al, Corporation	Polymer stabilized neuropeptides

2002
- 2002-05-08 EE EEP200300559A patent/EE200300559A/xx unknown
- 2002-05-08 YU YU89503A patent/YU89503A/sh unknown
- 2002-05-08 MX MXPA03010327A patent/MXPA03010327A/es active IP Right Grant
- 2002-05-08 IL IL15886702A patent/IL158867A0/xx unknown
- 2002-05-08 US US10/477,876 patent/US7217687B2/en not_active Expired - Fee Related
- 2002-05-08 KR KR1020037014773A patent/KR100947424B1/ko not_active Expired - Fee Related
- 2002-05-08 PL PL367065A patent/PL211763B1/pl not_active IP Right Cessation
- 2002-05-08 SK SK1423-2003A patent/SK14232003A3/sk unknown
- 2002-05-08 CN CNA2006101317669A patent/CN1939538A/zh active Pending
- 2002-05-08 HR HR20030840A patent/HRP20030840A2/hr not_active Application Discontinuation
- 2002-05-08 CZ CZ20033109A patent/CZ20033109A3/cs unknown
- 2002-05-08 EA EA200301253A patent/EA006655B1/ru not_active IP Right Cessation
- 2002-05-08 BR BR0209812-1A patent/BR0209812A/pt not_active IP Right Cessation
- 2002-05-08 CN CNB028144627A patent/CN1286524C/zh not_active Expired - Fee Related
- 2002-05-08 NZ NZ528852A patent/NZ528852A/en not_active IP Right Cessation
- 2002-05-08 HU HU0400005A patent/HUP0400005A3/hu unknown
- 2002-05-08 AU AU2002312886A patent/AU2002312886B2/en not_active Ceased
- 2002-05-08 UA UA20031110269A patent/UA85368C2/ru unknown
- 2002-05-08 EP EP02738042A patent/EP1389130B1/en not_active Expired - Lifetime
- 2002-05-08 AT AT02738042T patent/ATE555803T1/de active
- 2002-05-08 ES ES02738042T patent/ES2387082T3/es not_active Expired - Lifetime
- 2002-05-08 JP JP2002589038A patent/JP4417632B2/ja not_active Expired - Fee Related
- 2002-05-08 CA CA002443964A patent/CA2443964A1/en not_active Abandoned
- 2002-05-08 WO PCT/EP2002/005081 patent/WO2002092122A2/en not_active Ceased
2003
- 2003-10-13 ZA ZA200307956A patent/ZA200307956B/en unknown
- 2003-11-10 BG BG108337A patent/BG108337A/bg unknown
- 2003-11-12 NO NO20035025A patent/NO20035025D0/no not_active Application Discontinuation
- 2003-11-13 IL IL158867A patent/IL158867A/en not_active IP Right Cessation
2004
- 2004-11-05 US US10/981,737 patent/US7297099B2/en not_active Expired - Fee Related
2007
- 2007-02-27 US US11/679,735 patent/US20070225214A1/en not_active Abandoned
- 2007-11-07 US US11/936,623 patent/US20080213234A1/en not_active Abandoned
2009
- 2009-06-05 JP JP2009136621A patent/JP5036761B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US7297099B2 (en)	2007-11-20
SK14232003A3 (sk)	2004-05-04
HK1067051A1 (en)	2005-04-01
HRP20030840A2 (en)	2005-08-31
JP2004536058A (ja)	2004-12-02
JP5036761B2 (ja)	2012-09-26
UA85368C2 (ru)	2009-01-26
JP2009191082A (ja)	2009-08-27
PL211763B1 (pl)	2012-06-29
ZA200307956B (en)	2004-10-13
US7217687B2 (en)	2007-05-15
US20050176639A1 (en)	2005-08-11
US20080213234A1 (en)	2008-09-04
PL367065A1 (en)	2005-02-21
US20040235720A1 (en)	2004-11-25
WO2002092122A3 (en)	2003-03-06
CA2443964A1 (en)	2002-11-21
CZ20033109A3 (en)	2004-06-16
NO20035025L (no)	2003-11-12
EP1389130B1 (en)	2012-05-02
EA006655B1 (ru)	2006-02-24
KR100947424B1 (ko)	2010-03-12
EE200300559A (et)	2004-02-16
IL158867A (en)	2010-05-17
US20070225214A1 (en)	2007-09-27
CN1286524C (zh)	2006-11-29
EA200301253A1 (ru)	2004-06-24
YU89503A (sh)	2006-05-25
ES2387082T3 (es)	2012-09-13
NO20035025D0 (no)	2003-11-12
BG108337A (bg)	2004-12-30
ATE555803T1 (de)	2012-05-15
JP4417632B2 (ja)	2010-02-17
IL158867A0 (en)	2004-05-12
CN1939538A (zh)	2007-04-04
AU2002312886B2 (en)	2007-10-25
KR20040008176A (ko)	2004-01-28
WO2002092122A2 (en)	2002-11-21
EP1389130A2 (en)	2004-02-18
MXPA03010327A (es)	2004-02-17
BR0209812A (pt)	2004-06-01
HUP0400005A2 (hu)	2004-04-28
NZ528852A (en)	2005-12-23
CN1533283A (zh)	2004-09-29

Publication	Publication Date	Title
HUP0400005A3 (en)	2012-09-28	Use of osteopontin for the treatment and/or prevention of neurologic diseases
EP1392292A4 (en)	2004-08-11	PYRANOINDAZOLES AND THEIR USE IN GLAUCOMA TREATMENT
AU8870701A (en)	2002-03-13	Materials and methods for the treatment or prevention of obesity
AU2003290548A8 (en)	2004-06-07	Prevention and treatment of synucleinopathic disease
IL161110A0 (en)	2004-08-31	Prevention and treatment of restenosis by local admistration of drug
TWI347188B (en)	2011-08-21	Treatment and prevention of osteoporosis
AU2002345255A1 (en)	2003-01-21	Composition comprising soy and use thereof in the prevention and/or treatment of various diseases
ZA200208228B (en)	2005-07-27	Use of il-18 inhibitors for the treatment and/or prevention of athesclerosis
AU2002364171A8 (en)	2003-06-30	Materials and methods for the treatment or prevention of obesity
IL158206A0 (en)	2004-05-12	Compositions and methods for the prevention and treatment of human prostate cancer
AU2002247973A1 (en)	2002-09-24	Use of epigallocatechin-3-gallate or its derivatives in the prevention and treatment of neurodegenerative diseases
HUP0303306A3 (en)	2005-12-28	Use of il-18 inhibitors for the treatment and/or prevention of heart disease
GB0128674D0 (en)	2002-01-23	Treatment of sleep disorders and the like
GB0115707D0 (en)	2001-08-22	Treatment and prevention of lipodermatosclerosis
PL368035A1 (en)	2005-03-21	Compositions and methods for the treatment of cancer
HUP0302738A3 (en)	2010-01-28	Use of sarp-1 for the treatment and/or prevention of scleroderma
HUP0401913A3 (en)	2008-02-28	Medicine for preventing and treating bromhidrosis
EP1455780A4 (en)	2005-04-06	NEW BENZODIFURANIMIDAZOLIN AND BENZOFURANIMIDAZOLIN DERIVATIVES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA
EP1420798A4 (en)	2007-07-25	TREATMENT AND PREVENTION OF DISEASES AND CONDITIONS RELATED TO HEAT SHOCK PROTEIN
EP1472273A4 (en)	2005-01-26	COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
HUP0105310A3 (en)	2002-08-28	Use of phosphororganic compounds for the prophylactic and therapeutical treatment of infections
GB0113910D0 (en)	2001-08-01	Treatment of liquids
AU2002366195A8 (en)	2003-06-10	Use of bisindolmaleimide and gemcitabine for the treatment of cancer
AU2001267165A1 (en)	2002-01-14	Prevention and treatment of mycoplasma-associated diseases
EP1392460A4 (en)	2009-11-04	AMINOSILANOL HYDROFLUORIDES AND THEIR USE

Legal Events

Date	Code	Title	Description
2007-12-28	GB9A	Succession in title	Owner name: LABORATOIRES SERONO SA, CH Free format text: FORMER OWNER(S): APPLIED RESEARCH SYSTEMS ARS HOLDING N.V., NL
2013-11-28	FA9A	Lapse of provisional patent protection due to relinquishment or protection considered relinquished

Date

Code

Title

Description

2007-12-28

GB9A

Succession in title

Owner name: LABORATOIRES SERONO SA, CH

Free format text: FORMER OWNER(S): APPLIED RESEARCH SYSTEMS ARS HOLDING N.V., NL

2013-11-28

FA9A

Lapse of provisional patent protection due to relinquishment or protection considered relinquished